Crispr Therapeutics AG (NASDAQ:CRSP) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 3,140,000 shares, an increase of 9.8% from the February 13th total of 2,860,000 shares. Approximately 11.9% of the shares of the company are sold short. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 2.9 days.
CRSP traded down $1.11 during trading hours on Monday, hitting $36.53. 549,637 shares of the company’s stock were exchanged, compared to its average volume of 1,083,612. Crispr Therapeutics has a 1-year low of $33.55 and a 1-year high of $74.00. The stock’s 50-day moving average is $52.49 and its two-hundred day moving average is $53.35. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of 37.66 and a beta of 2.74.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $1.19. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm had revenue of $77.00 million for the quarter, compared to analyst estimates of $39.08 million. During the same period in the previous year, the business earned ($0.92) EPS. The company’s revenue was up 76900.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Crispr Therapeutics will post -4.54 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of CRSP. Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter worth approximately $21,167,000. FMR LLC increased its stake in Crispr Therapeutics by 71.8% in the 4th quarter. FMR LLC now owns 952,369 shares of the company’s stock worth $58,004,000 after purchasing an additional 398,012 shares during the period. Renaissance Technologies LLC raised its holdings in Crispr Therapeutics by 904.0% during the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the company’s stock valued at $24,031,000 after buying an additional 355,264 shares during the last quarter. Nikko Asset Management Americas Inc. raised its stake in shares of Crispr Therapeutics by 9.8% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,049,553 shares of the company’s stock valued at $185,733,000 after acquiring an additional 272,139 shares during the last quarter. Finally, Capital International Investors raised its stake in shares of Crispr Therapeutics by 171.7% during the fourth quarter. Capital International Investors now owns 375,000 shares of the company’s stock valued at $22,839,000 after acquiring an additional 237,000 shares during the last quarter. 52.04% of the stock is currently owned by institutional investors.
A number of analysts have recently weighed in on CRSP shares. Citigroup boosted their price objective on shares of Crispr Therapeutics from $28.00 to $31.00 and gave the stock a “sell” rating in a research note on Wednesday, March 4th. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 17th. Piper Sandler reiterated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Canaccord Genuity boosted their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $73.04.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: 52-Week High/Low
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.